Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Introductions and evolutions of SARS-CoV-2 strains in Japan

View ORCID ProfileReitaro Tokumasu, View ORCID ProfileDilhan Weeraratne, View ORCID ProfileJane Snowdon, View ORCID ProfileLaxmi Parida, View ORCID ProfileMichiharu Kudo, View ORCID ProfileTakahiko Koyama
doi: https://doi.org/10.1101/2021.02.26.21252555
Reitaro Tokumasu
1IBM Research- Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Reitaro Tokumasu
Dilhan Weeraratne
2IBM Watson Health, Cambridge, MA 02142, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dilhan Weeraratne
Jane Snowdon
2IBM Watson Health, Cambridge, MA 02142, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jane Snowdon
Laxmi Parida
3IBM TJ Watson Research Center, Yorktown Heights, NY 10598, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laxmi Parida
Michiharu Kudo
1IBM Research- Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michiharu Kudo
Takahiko Koyama
3IBM TJ Watson Research Center, Yorktown Heights, NY 10598, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Takahiko Koyama
  • For correspondence: tkoyama{at}us.ibm.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

COVID-19 caused by SARS-CoV-2 was first identified in Japan on January 15th, 2020, soon after the pandemic originated in Wuhan, China. Subsequently, Japan experienced three distinct waves of the outbreak in the span of a year and has been attributed to new exogenous strains and evolving existing strains. Japan engaged very early on in tracking different COVID-19 strains and have sequenced approximately 5% of all confirmed cases. While Japan has enforced stringent airport surveillance on cross-border travelers and returnees, some carriers appear to have advanced through the quarantine stations undetected. In this study 30493 genomes sampled in Japan were analyzed to understand the strains, heterogeneity and temporal evolution of different SARS-CoV-2 strains. We identified 12 discrete strains with a substantial number of cases with most strains possessing the spike (S) D614G and nucleocapsid (N) 203_204delinsKR mutations. 155 distinct strains have been introduced into Japan and 39 of them were introduced after strict quarantine policy was implemented. In particular, the B.1.1.7 strain, that emerged in the United Kingdom (UK) in September 2020, has been circulating in Japan since late 2020 after eluding cross-border quarantine stations. Similarly, the B.1.351 strain dubbed the South African variant, P.1 Brazilian strain and R.1 strain with the spike E484K mutation have been detected in Japan. At least 14 exogenous B.1.1.7 sub-strains have been independently introduced in Japan as of late March 2021, and these strains carry mutations that give selective advantage including N501Y, H69_V70del, and E484K that confer increased transmissibility, reduced efficacy to vaccines and possible increased virulence. Furthermore, various strains, which harbor multiple variants in the PCR primers and the probe developed by National Institute of Infectious Disease (NIID), are emerging. It is imperative that the quarantine policy be revised, cross-border surveillance reinforced, and new public health measures implemented to mitigate further transmission of this deadly disease and to identify strains that may engender resistance to vaccines.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors received no specific funding for this work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Since we focus on Japanese SARS-CoV-2 epidemiological status with publicly available virus genomes data and don't include any IRB' related issues, this study is an exemption of IRB approval.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ・Analysis update with newly available genomes in japan ・Reclassify discrete strains (added B117, R1, and D614G_KR_M234I_A90T strains. removed D614G_KR_V70I and E972K strains)

Data Availability

All genome data used in the study is listed in supplemental table and available at GISAID and NCBI. COVID-19 case and death number in japan is available at Our World in Data.

https://www.ncbi.nlm.nih.gov/

https://www.gisaid.org/

https://ourworldindata.org/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted May 14, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Introductions and evolutions of SARS-CoV-2 strains in Japan
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Introductions and evolutions of SARS-CoV-2 strains in Japan
Reitaro Tokumasu, Dilhan Weeraratne, Jane Snowdon, Laxmi Parida, Michiharu Kudo, Takahiko Koyama
medRxiv 2021.02.26.21252555; doi: https://doi.org/10.1101/2021.02.26.21252555
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Introductions and evolutions of SARS-CoV-2 strains in Japan
Reitaro Tokumasu, Dilhan Weeraratne, Jane Snowdon, Laxmi Parida, Michiharu Kudo, Takahiko Koyama
medRxiv 2021.02.26.21252555; doi: https://doi.org/10.1101/2021.02.26.21252555

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (760)
  • Anesthesia (222)
  • Cardiovascular Medicine (3316)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (480)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13403)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5181)
  • Geriatric Medicine (483)
  • Health Economics (786)
  • Health Informatics (3286)
  • Health Policy (1146)
  • Health Systems and Quality Improvement (1199)
  • Hematology (432)
  • HIV/AIDS (1024)
  • Infectious Diseases (except HIV/AIDS) (14657)
  • Intensive Care and Critical Care Medicine (917)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (526)
  • Neurology (4957)
  • Nursing (263)
  • Nutrition (735)
  • Obstetrics and Gynecology (889)
  • Occupational and Environmental Health (797)
  • Oncology (2531)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1308)
  • Pharmacology and Therapeutics (552)
  • Primary Care Research (559)
  • Psychiatry and Clinical Psychology (4224)
  • Public and Global Health (7526)
  • Radiology and Imaging (1717)
  • Rehabilitation Medicine and Physical Therapy (1022)
  • Respiratory Medicine (982)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (73)
  • Transplantation (237)
  • Urology (206)